Article info
Inflammatory bowel disease
A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease
- Correspondence to Dr Iris Dotan, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel; irisd{at}tasmc.health.gov.il
Citation
A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease
Publication history
- Revised February 5, 2010
- Accepted February 8, 2010
- First published May 13, 2010.
Online issue publication
May 13, 2010
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.